---
title: Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student
nct_id: NCT02931747
overall_status: COMPLETED
phase: PHASE1
sponsor: Khon Kaen University
study_type: INTERVENTIONAL
primary_condition: Healthy
countries: Thailand
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02931747.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02931747"
ct_last_update_post_date: 2017-08-18
last_seen_at: "2026-05-12T07:30:02.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student

**NCT ID:** [NCT02931747](https://clinicaltrials.gov/study/NCT02931747)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 75
- **Lead Sponsor:** Khon Kaen University
- **Collaborators:** Government Pharmaceutical Organization
- **Conditions:** Healthy
- **Start Date:** 2016-07
- **Completion Date:** 2017-03
- **CT.gov Last Update:** 2017-08-18

## Brief Summary

The purpose of this study is to determine the effect of Bacopa Monnieri on working memory and cognitive processing in student.

## Detailed Description

Learning and working memory are two of the key role for studying and work successful for student particular the high school student who study hard and preparing themselves for the graduate study. The consumption of brain booster product or functional food for improving memory has gained much attention. It has been reported that Bacopa Monnieri could improve learning and working memory in elderly subject by improving the N100 and P300 event related potential. Therefore, Bacopa Monnieri might be the potential product for improving the learning and working memory in student particular high school student.

## Eligibility

- **Minimum age:** 15 Years
- **Maximum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy student subject aged between 15-18 years old who studying in the school within Khon Kaen province.
* Body mass index is between 18.5-24.9

Exclusion Criteria:

* Subjects who are diagnosed with one of the following: cardiovascular diseases, respiratory disease, neuropsychological diseases, head injury, diabetes mellitus, liver disease, cancer, autoimmune disease and hematological disorder are excluded.
* Subjects who take any medicine or nutraceuticals or hormone that effect on central nervous system are excluded.
* Alcohol addict or smoking addiction (more than 10 pieces/day)
* Athlete or subjects who have a regular exercise more than 3 times/week
* Subjects who don't follow the instruction during the trial
* Subjects who are participating the other project.
```

## Arms

- **Placebo** (PLACEBO_COMPARATOR) — Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
- **Bacopa Monnieri 300 mg/day** (ACTIVE_COMPARATOR) — Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
- **Bacopa Monnieri 600 mg/day** (ACTIVE_COMPARATOR) — Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks

## Interventions

- **Placebo** (DIETARY_SUPPLEMENT) — Subjects are received Placebo once daily for 16 weeks.
- **Bacopa Monnieri 300 mg/day** (DIETARY_SUPPLEMENT) — Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
- **Bacopa Monnieri 600 mg/day** (DIETARY_SUPPLEMENT) — Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.

## Primary Outcomes

- **Cognitive processing using the latency of P300 wave** _(time frame: 4 months)_ — The latency of P300 wave was measured and expressed as millisecond.
- **Cognitive processing using the amplitude of P300 wave** _(time frame: 4 months)_ — The amplitude of P300 wave was measured and expressed as micro-volt.
- **Attention using the latency of N100 wave** _(time frame: 4 months)_ — The latency of N100 wave was measured and expressed as millisecond.
- **Attention using the amplitude of N100 wave** _(time frame: 4 months)_ — The amplitude of N100 wave was measured and expressed as micro-volt.

## Secondary Outcomes

- **Accuracy of working memory using computerized battery test** _(time frame: 4 months)_
- **Speed of working memory using computerized battery test** _(time frame: 4 months)_
- **Assessment of psychiatric symptoms using the symptom check list 90 (SCL-90)** _(time frame: 4 months)_
- **Assessment of mood scale using Bond-Lader visual analogue scales** _(time frame: 4 months)_
- **Acetylcholinesterase activity in serum** _(time frame: 4 months)_
- **Monoamine oxidase activity in serum** _(time frame: 4 months)_
- **Glutamic acid decarboxylase (GAD) activity in serum** _(time frame: 4 months)_
- **Gamma-aminobutyric acid (GABA)-transaminase in serum** _(time frame: 4 months)_
- **Malondialdehyde level in serum** _(time frame: 4 months)_
- **Activity of superoxide dismutase in serum** _(time frame: 4 month)_
- **Activity of catalase in serum** _(time frame: 4 month)_
- **Activity of glutathione peroxidase in serum** _(time frame: 4 month)_
- **Consumption safety of Bacopa Monnieri using electrocardiogram (EKG)** _(time frame: 4 month)_
- **Consumption safety of Bacopa Monnieri using hematological values .** _(time frame: 4 month)_
- **Consumption safety of Bacopa Monnieri using blood chemistry** _(time frame: 4 month)_
- **Consumption safety of Bacopa Monnieri using blood pressure measurement** _(time frame: 4 month)_

## Locations (1)

- Jitanaporn Wattanathorn, Khon Kaen, Thailand

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.jitanaporn wattanathorn|khon kaen||thailand` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02931747.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02931747*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*